看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | -17.3x - -19.1x | -18.2x |
| Selected Fwd EBITDA Multiple | -21.1x - -23.3x | -22.2x |
| Fair Value | kr415.30 - kr446.13 | kr430.72 |
| Upside | -2.2% - 5.1% | 1.5% |
| Benchmarks | Ticker | Full Ticker |
| Genmab A/S | GMAB | CPSE:GMAB |
| DBV Technologies S.A. | DBV | ENXTPA:DBV |
| Molecular Partners AG | MOLN | SWX:MOLN |
| Basilea Pharmaceutica AG | BSLN | SWX:BSLN |
| argenx SE | ARGX | ENXTBR:ARGX |
| Zealand Pharma A/S | ZEAL | CPSE:ZEAL |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| GMAB | DBV | MOLN | BSLN | ARGX | ZEAL | ||
| CPSE:GMAB | ENXTPA:DBV | SWX:MOLN | SWX:BSLN | ENXTBR:ARGX | CPSE:ZEAL | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | 21.6% | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | 32.9% | NM- | NM- | 160.7% | NM- | NM- | |
| Latest Twelve Months | 33.7% | NM | -0.1% | 172.3% | 94.8% | -126.9% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 44.8% | -1431.2% | -558.3% | 4.9% | -201.5% | -618.0% | |
| Prior Fiscal Year | 33.6% | -402.3% | -855.1% | 14.7% | -25.0% | -161.8% | |
| Latest Fiscal Year | 34.3% | NA | -1211.9% | 30.3% | -0.7% | -2007.4% | |
| Latest Twelve Months | 34.3% | NA | -1211.9% | 30.3% | -0.7% | -2007.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.87x | 29.02x | -6.43x | 2.35x | 14.44x | 340.54x | |
| EV / LTM EBITDA | 8.4x | NA | 0.5x | 7.8x | -1989.4x | -17.0x | |
| EV / LTM EBIT | 8.7x | -1.0x | 0.5x | 8.0x | -1819.8x | -16.8x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -1989.4x | 4.2x | 8.4x | ||||
| Historical EV / LTM EBITDA | -36.9x | -14.8x | -6.2x | ||||
| Selected EV / LTM EBITDA | -17.3x | -18.2x | -19.1x | ||||
| (x) LTM EBITDA | (1,258) | (1,258) | (1,258) | ||||
| (=) Implied Enterprise Value | 21,798 | 22,945 | 24,092 | ||||
| (-) Non-shareholder Claims * | 8,654 | 8,654 | 8,654 | ||||
| (=) Equity Value | 30,452 | 31,599 | 32,746 | ||||
| (/) Shares Outstanding | 70.7 | 70.7 | 70.7 | ||||
| Implied Value Range | 430.85 | 447.08 | 463.32 | ||||
| FX Rate: DKK/DKK | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 430.85 | 447.08 | 463.32 | 424.50 | |||
| Upside / (Downside) | 1.5% | 5.3% | 9.1% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | GMAB | DBV | MOLN | BSLN | ARGX | ZEAL | |
| Enterprise Value | 61,614 | 125 | (30) | 492 | 32,971 | 21,349 | |
| (+) Cash & Short Term Investments | 21,101 | 32 | 149 | 121 | 3,379 | 8,226 | |
| (+) Investments & Other | 228 | 4 | 0 | 0 | 50 | 820 | |
| (-) Debt | (1,029) | (7) | (2) | (112) | (39) | (392) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 81,914 | 155 | 117 | 501 | 36,360 | 30,003 | |
| (/) Shares Outstanding | 63.4 | 102.6 | 36.9 | 12.1 | 61.0 | 70.7 | |
| Implied Stock Price | 1,291.50 | 1.51 | 3.16 | 41.30 | 596.16 | 424.50 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.14 | 1.00 | 1.00 | 1.14 | 1.00 | |
| Implied Stock Price (Trading Cur) | 1,291.50 | 1.33 | 3.16 | 41.30 | 524.20 | 424.50 | |
| Trading Currency | DKK | EUR | CHF | CHF | EUR | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.14 | 1.00 | 1.00 | 1.14 | 1.00 | |